01643 MODERN CHI MED
- 0.395
- -0.010-2.47%
MODERN CHI MED News
Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year
現代中藥集團：2023年報
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Express News | Guojin Securities: Focus on opportunities such as in vitro diagnostic collection clean-up and proprietary Chinese medicine collection
Express News | Capital Securities: The high dividend rate in the Chinese medicine industry is stable and sustainable
Have Insiders Sold Modern Chinese Medicine Group Shares Recently?
We wouldn't blame Modern Chinese Medicine Group Co., Ltd. (HKG:1643) shareholders if they were a little worried about the fact that Xinlei Sun, the Executive Chairman recently netted about HK$18m sell
Modern Biotechnology Group Holdings Co., Ltd. OTC sale of 48 million shares of Modern Chinese Medicine Group (01643.HK) common shares worth approximately HK$18 million
On March 27, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on March 27, Modern Biotechnology Group Holdings Co., Ltd. Modern Biotechnology Group Holdings Limited sold $48 million of $Modern Chinese Medicine Group (01643.HK) common shares worth approximately HK$18 million on March 21 at an average price of HK$0.375 per share. After the sale, Modern Biotechnology Group Holdings Co., Ltd.
Modern Chinese Medicine Group (01643.HK) profit before tax fell 45.1% to 68.3 million yuan in 2023
Gelonghui March 22 | Modern Chinese Medicine Group (01643.HK) announced that for the year ended December 31, 2023, the Group recorded revenue of approximately RMB 344.1 million in 2023, a decrease of approximately RMB 55.6 million or 13.9% compared with the fiscal year ending 2022. The decline in revenue was mainly due to changes in government policies, which led to a decrease in orders from dealers. Profit before tax decreased by about 45.1% from about RMB 124.3 million in 2022 to about RMB 68.3 million as of 2023, mainly due to changes in government policies, the decrease in dealer orders
MODERN CHI MED: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Modern Chinese Medicine Group (01643.HK) plans to hold a board meeting on March 22 to consider and approve the annual results
Gelonghui, March 13, 丨 Modern Chinese Medicine Group (01643.HK) announced that the company will hold a board meeting on March 22, 2024 (Friday). The agenda includes considering and approving the annual results of the company and its subsidiaries for the year ended 31 December 2023 and considering payment of a final dividend proposal (if any).
MODERN CHI MED: DATE OF BOARD MEETING
Modern Chinese Medicine Warns of Up to 48% Profit Slump
Modern Chinese Medicine Group (HKG:1643) expects a net profit of between 46 million yuan and 51 million yuan for the year 2023, down 42% to 48% from 87.8 million yuan in 2022, according to a filing wi
Hyundai Traditional Chinese Medicine Group (01643) issued a profit warning. The estimated annual net profit of 46 million yuan to 51 million yuan decreased by about 42% to 48% year-on-year
Hyundai Chinese Medicine Group (01643) issued an announcement. It is expected that the Group will take...
MODERN CHI MED: PROFIT WARNING
Express News | Debon Securities: Traditional Chinese medicine allocation is cost-effective, focus on small and medium capitalization stocks that have overfallen
Express News | China Post Securities: The valuation of the Chinese medicine sector is currently at a low level
R&D investment from listed Chinese medicine companies continues to rise, and the development of innovative traditional Chinese medicine drugs enters the “fast track” |Chinese medicine 2024 outlook
Financial Services Association, Feb. 21 (Reporters Zhang Liangde and Wang Pingan) In recent years, in the context of national policies supporting development, traditional Chinese medicine companies are facing unprecedented development opportunities.
Express News | Wanlian Securities: The overall valuation level of the Chinese medicine industry is at a historically low level
Medical insurance relief restrictions for traditional Chinese medicine injections to open a 100 billion market? |Traditional Chinese Medicine 2024 Outlook
① An industry insider told the Financial Federation reporter: “As restrictions on some varieties of traditional Chinese medicine injections are lifted, the market may reach 100 billion in the next few years.” ② In addition to the acceleration of sales in the traditional Chinese medicine injection market due to medical insurance restrictions, the return to normal in-hospital diagnosis and treatment services in the post-pandemic era is also beneficial to the increase in overall injection market sales.
Traditional Chinese medicine formula market development accelerates collection and starts industry “big fish eat small fish” ahead of schedule | Traditional Chinese medicine 2024 outlook
Financial Services Association, Feb. 18 (Reporters Zhang Liangde and Wang Pingan) Due to the continuous entry of new players after the completion of the pilot (policy) of the traditional Chinese medicine formula industry and the “unexpected advance” of collection in 15 provinces, the traditional Chinese medicine formula granule market pattern may face reshaping. Some industry insiders said that the industry may enter the “big fish eat small fish” stage.
Analysis
Price Target
No Data
